Shavy Makh

Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE

S. Galetta, R. Fox, C. Hotermans, 2019, BMC Neurology.

Randomized phase I clinical trial of anti–α‐synuclein antibody BIIB054

J. Cedarbaum, N. Penner, M. Brys, 2019, Movement disorders : official journal of the Movement Disorder Society.

Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of Anti-Alpha-Synuclein Antibody BIIB054 in Patients with Parkinson’s Disease (S26.001)

J. Cedarbaum, M. Brys, Minhua Yang, 2018 .